News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Stocktwits Analyst action
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Novavax Inc. (NVAX) shares rose 2.26% to $8.14, outperforming major indices like the NASDAQ Composite and Dow Jones Industrial Average. This marked the third consecutive day of gains for the stock. The positive performance occurred during a favorable trading session for the broader market.
Novavax (NVAX) reported a significant second-quarter revenue drop to US$56.7 million from US$239.24 million, resulting in a net loss of US$53.39 million, and filed an US$82.47 million shelf registration for new shares. This shift from profitability to loss, alongside potential share dilution, raises concerns …
Novavax, Inc. (NVAX), a biotechnology company specializing in vaccines, shows a promising potential upside of 77.47% according to analyst ratings, despite current financial challenges including a 76.30% revenue decline. The company's strategic partnerships and product pipeline, including Nuvaxovid and the R21 Matrix-M malaria vaccine, …
Renaissance Technologies LLC has acquired a new position in Novavax, Inc. (NASDAQ:NVAX), purchasing 497,383 shares valued at approximately $4.05 million. This investment represents a 0.30% stake in Novavax, which recently reported better-than-expected Q2 earnings, though revenue fell significantly year-over-year. The biopharmaceutical company has a …
In early August 2026, Novavax reported Q2 2026 revenue of US$56.7 million, sharply lower than the prior year, and moved from net income to a net loss of US$53.39 million, translating into basic and diluted losses of US$0.32 per share from continuing operations. Alongside …
Sharemaestro market context Price below Trend Line 52 weeks -4.5%Novavax NVAX incurred a loss of 32 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 36 cents. In the year-ago quarter, the company had recorded earnings per share (EPS) of 62 cents, driven …
Sharemaestro market context Price below Trend Line 52 weeks -4.5%Novavax, Inc.'s average 12-month price target has been reduced to $13.75 from $13.88, according to 8 analysts, with forecasts ranging from $7 to $25 per share. This new target implies a potential 78% upside based on the Aug. 6 closing price. The consensus analyst …
Novavax Inc. (NVAX) reported its Q2 2026 earnings, highlighting significant progress with its Matrix-M adjuvant technology through partnerships with top pharmaceutical companies, including Sanofi. The company increased its full-year 2026 revenue guidance to $235 million-$275 million, driven by strong demand for Matrix-M, and aims …
Novavax (NVAX) reported a Q2 loss of $0.32 per share, outperforming the Zacks Consensus Estimate of a $0.36 loss, and topped revenue estimates with $56.7 million. This marks the fourth consecutive quarter the company has surpassed both EPS and revenue expectations. Despite a year-over-year …
Novavax has increased its annual revenue forecast, driven by licensing and supply agreements for its vaccine platform rather than direct vaccine sales. The company is strategically shifting its focus to these partnerships, particularly with Sanofi, to achieve profitability by 2028, even as its second-quarter …
Novavax (NASDAQ: NVAX) exceeded Wall Street's Q2 earnings expectations, leading to a bump in its 2026 revenue guidance. The biotechnology company reported $57 million in revenue, driven by increased product sales despite a significant year-over-year decline due to the absence of large partner payments …
Novavax (NVAX) shares rose after the company reported better-than-expected Q2 2026 financials, beating revenue estimates by $3.7 million with $57 million in revenue. Following this performance, the COVID-19 vaccine maker also raised its full-year revenue guidance.
Novavax reported a significant financial downturn in Q2 2026, swinging to a $53 million net loss from a $107 million net income in Q2 2025, with total revenue decreasing by 76% to $57 million. This drop is primarily attributed to the absence of large …
NOVAVAX INC reported a significant decline in its second-quarter 2026 financial results, with revenue falling to $56.7 million and a net loss of $53.39 million, primarily due to fewer one-time milestone and agreement-related items compared to the prior year. The company's business strategy has …
Novavax, Inc. (NVAX) announced its Q2 revenue of $56.7 million, surpassing the FactSet estimate of $52.5 million. This earnings flash indicates the company's financial performance for the quarter, highlighting better-than-expected revenue generation.
Novavax announced its Q2 2026 financial results, reporting $57 million in total revenue and raising its full-year 2026 revenue framework to between $235 million and $275 million. The company also improved its GAAP Combined R&D and SG&A expense guidance. Key operational highlights include continued …
Novavax is set to report its second-quarter earnings, with investors focused on whether its new partnership strategy can compensate for declining COVID-19 vaccine sales. Analysts anticipate a significant revenue decrease and a loss per share, despite a "buy" rating from Wall Street analysts. The …
This article provides a price-driven analysis for Novavax Inc. (NVAX) using AI models, outlining distinct trading strategies for various risk profiles. It highlights a positive near-term sentiment with potential mid-term weak bias within long-term strength, and identifies key support and resistance levels. The analysis …
Novavax Inc is projected to report a loss of 39 cents per share, according to this earnings preview. The full article is available through TradingView News, which aggregates content from various sources including Reuters. This financial forecast provides a key insight into the company's …
Novavax (NVAX) stock rose ahead of its Q2 earnings release, as the company continues to pivot its strategy from large-scale COVID-19 vaccine sales to licensing its proprietary Matrix-M adjuvant. Investors are anticipating updates on cash position and progress with Matrix-M deals, especially after a …
Search by ticker symbol or company name and select a result to open its chart.